Analysts rate Vicarious Surgical Inc.(RBOT:NYE) with a Strong Buy, $12 Target

STA Research
by: STA Research

Analysts rate Vicarious Surgical with a consensus Strong Buy rating and a 12-month average Target price of $12.33 per share.

Piper Sandler downgraded  Vicarious Surgical to Neutral,  and slashed the Target from $16 to $7.

Based on the Vicarious Surgical Inc. stock forecasts from 4 analysts, the average analyst target price for Vicarious Surgical Inc. is USD 12.33 over the next 12 months. Vicarious Surgical Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Vicarious Surgical Inc. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Vicarious Surgical Inc.’s stock price was USD 5.02. Vicarious Surgical Inc.’s stock price has changed by -0.83% over the past week, -1.36% over the past month and +0.00% over the last year.

Adam Sachs, Sammy Khalifa, and Dr. Barry Greene created Vicarious Surgical in 2014. The founders were inspired by the film Fantastic Voyage, in which doctors shrink in size to travel within the human body, and their ambition was to allow surgeons to do the same. Not only did the solution require a completely separate design of robotic architecture, but also of the actuators themselves.



Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.